OPB-31121
- Generic Name
- OPB-31121
Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: OPB-31121 phase2
- First Posted Date
- 2011-08-01
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT01406574
Study to Assess OPB-31121 in Advanced Leukemias or Myelodysplastic Syndromes
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2012-07-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01029509
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
STAT3 Inhibitor for Solid Tumors
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00955812
- Locations
- 🇺🇸
Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
An Open-Label Phase-1 Study of OPB-31121 in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Solid Tumor
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2008-04-18
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT00657176
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
- First Posted Date
- 2007-08-03
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Otsuka Beijing Research Institute
- Target Recruit Count
- 7
- Registration Number
- NCT00511082
- Locations
- ðŸ‡ðŸ‡°
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath